Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Joins Up With Yale In Cancer Discovery Collaboration

This article was originally published in The Pink Sheet Daily

Executive Summary

The biotech has partnered with Yale University on cancer research in a deal that could provide $100 million in funding to Yale over 10 years.

You may also be interested in...



Gilead, JAKed About Cancer Research, Buys YM BioScienses

Gilead will buy the Canadian cancer specialist for $510 million, gaining the lead drug CYT387, a JAK1/JAK2 inhibitor that has demonstrated positive results in myelofibrosis patients.

Gilead Springs Further Into Oncology With Calistoga Acquisition

Dominant in HIV, the biotech pays $375 million up front for Seattle-based Calistoga and its closely-watched PI3K program.

Pfizer Signs Up Seven New York Institutions To Create Biomedical Discovery Engine

New York deals follow UCSF tie-up in San Francisco; six more city-based alliances are to come.

Topics

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel